The 3 + 3 dose escalation design is not appropriate for antivenom dose finding.
Chippaux
Jean-Philippe
JP
Boyer
Leslie
L
D000997:Antivenins / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020714:Maximum Tolerated Dose; D012107:Research Design; D018570:Risk Assessment; D012909:Snake Bites / Q000188:drug therapy
D000997:Antivenins